{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:46:27Z","timestamp":1792089987161,"version":"4.4.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100019603","name":"Faculty of Medicine, American University of Beirut","doi-asserted-by":"publisher","award":["Scholarly Concentration Track"],"award-info":[{"award-number":["Scholarly Concentration Track"]}],"id":[{"id":"10.13039\/100019603","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019603","name":"Faculty of Medicine, American University of Beirut","doi-asserted-by":"publisher","award":["University Research Board (URB)\u2013103949; URB\u2013104262; URB\u2013104115; URB\u2013104524; Medical Practice Plan (MPP)\u2013320145"],"award-info":[{"award-number":["University Research Board (URB)\u2013103949; URB\u2013104262; URB\u2013104115; URB\u2013104524; Medical Practice Plan (MPP)\u2013320145"]}],"id":[{"id":"10.13039\/100019603","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"DOI":"10.1007\/s11883-026-01471-7","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:47:12Z","timestamp":1792086432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases"],"prefix":"10.1007","volume":"28","author":[{"given":"Fady G.","family":"Mikhael","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Teperikidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Biondi-Zoccai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W.","family":"Booz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad A.","family":"Zouein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisrine N.","family":"Makarem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"1471_CR1","unstructured":"Organization WH: Cardiovascular diseases (CVDs) fact sheet. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds) (2025). Accessed November 4 2025."},{"key":"1471_CR2","doi-asserted-by":"publisher","unstructured":"Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990\u20132023. J Am Coll Cardiol. 2025. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.015.","DOI":"10.1016\/j.jacc.2025.08.015"},{"issue":"1","key":"1471_CR3","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","volume":"42","author":"G Reyes-Soffer","year":"2022","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the american heart association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48\u201360. https:\/\/doi.org\/10.1161\/ATV.0000000000000147.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"39","key":"1471_CR4","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361.","journal-title":"Eur Heart J"},{"issue":"1","key":"1471_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","volume":"41","author":"AP Patel","year":"2021","unstructured":"Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, et al. Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease new insights from a large national biobank. Arterioscler Thromb Vasc Biol. 2021;41(1):465\u201374. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315291.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"1471_CR6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/jamacardio.2024.1882","volume":"9","author":"BJ Arsenault","year":"2024","unstructured":"Arsenault BJ, Loganath K, Girard A, Botezatu S, Zheng KH, Tzolos E, et al. Lipoprotein(a) and calcific aortic valve stenosis progression: a systematic review and meta-analysis. JAMA Cardiol. 2024;9(9):835\u201342. https:\/\/doi.org\/10.1001\/jamacardio.2024.1882.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"1471_CR7","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001.","journal-title":"Cell Metab"},{"issue":"4","key":"1471_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"19","key":"1471_CR9","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"1834","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"10193","key":"1471_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"issue":"1","key":"1471_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","volume":"24","author":"DJ Drucker","year":"2016","unstructured":"Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15\u201330. https:\/\/doi.org\/10.1016\/j.cmet.2016.06.009.","journal-title":"Cell Metab"},{"issue":"7","key":"1471_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463\u201374. https:\/\/doi.org\/10.1038\/s41569-023-00849-3.","journal-title":"Nat Rev Cardiol"},{"key":"1471_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000002712","author":"N Joshi","year":"2024","unstructured":"Joshi N, Baloch KM, Rukh S, Khan AM, Muskan F, Kumari V, et al. Unlocking the potential of glucagon-like peptide-1 receptor agonists in revolutionizing type 2 diabetes management: a comprehensive review. Ann Med Surg. 2024. https:\/\/doi.org\/10.1097\/MS9.0000000000002712.","journal-title":"Ann Med Surg"},{"key":"1471_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf193","author":"T Sasaki","year":"2025","unstructured":"Sasaki T, Giang SM-L, Wu J, Yokoo T, Gallagher M, Bellomo R, et al. The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2025. https:\/\/doi.org\/10.1093\/ndt\/gfaf193.","journal-title":"Nephrol Dial Transplant"},{"key":"1471_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100641","volume":"18","author":"G Kaur","year":"2024","unstructured":"Kaur G, Abdelrahman K, Berman AN, Biery DW, Shiyovich A, Huck D, et al. Lipoprotein(a): Emerging insights and therapeutics. Am J Prev Cardiol. 2024;18. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100641.","journal-title":"Am J Prev Cardiol"},{"issue":"11\u201312","key":"1471_CR16","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1055\/s-2004-826165","volume":"36","author":"GG Holz","year":"2004","unstructured":"Holz GG. New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells. Horm Metab Res. 2004;36(11\u201312):787\u201394. https:\/\/doi.org\/10.1055\/s-2004-826165.","journal-title":"Horm Metab Res"},{"issue":"8","key":"1471_CR17","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.7150\/ijbs.59965","volume":"17","author":"X Ma","year":"2021","unstructured":"Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A, et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021;17(8):2050\u201368. https:\/\/doi.org\/10.7150\/ijbs.59965.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"1471_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1463-1326.2012.01663.x","volume":"15","author":"AR Meloni","year":"2013","unstructured":"Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic \u03b2-cells: mechanism and glucose dependence. Diabetes Obes Metab. 2013;15(1):15\u201327. https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01663.x.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1471_CR19","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.jhep.2010.09.032","volume":"54","author":"S Ben-Shlomo","year":"2011","unstructured":"Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol. 2011;54(6):1214\u201323. https:\/\/doi.org\/10.1016\/j.jhep.2010.09.032.","journal-title":"J Hepatol"},{"issue":"5","key":"1471_CR20","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/hep.23569","volume":"51","author":"NA Gupta","year":"2010","unstructured":"Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010;51(5):1584\u201392. https:\/\/doi.org\/10.1002\/hep.23569.","journal-title":"Hepatology"},{"issue":"8","key":"1471_CR21","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.3390\/cimb44080239","volume":"44","author":"T Omanovic Kolaric","year":"2022","unstructured":"Omanovic Kolaric T, Kizivat T, Mihaljevic V, Zjalic M, Bilic-Curcic I, Kuna L, et al. Liraglutide exerts protective effects by downregulation of PPAR\u03b3, ACSL1 and SREBP-1c in Huh7 cell culture models of non-alcoholic steatosis and drug-induced steatosis. Curr Issues Mol Biol. 2022;44(8):3465\u201380. https:\/\/doi.org\/10.3390\/cimb44080239.","journal-title":"Curr Issues Mol Biol"},{"issue":"1","key":"1471_CR22","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1038\/s41598-022-06143-5","volume":"12","author":"O Khalifa","year":"2022","unstructured":"Khalifa O, Al-Akl NS, Errafii K, Arredouani A. Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt\/-catenin signaling pathway. Sci Rep. 2022;12(1):2226. https:\/\/doi.org\/10.1038\/s41598-022-06143-5.","journal-title":"Sci Rep"},{"issue":"21","key":"1471_CR23","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, \u00d8stergaard LH, Long MT, Kj\u00e6r MS, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2413258.","journal-title":"N Engl J Med"},{"key":"1471_CR24","doi-asserted-by":"publisher","first-page":"923606","DOI":"10.3389\/fendo.2022.923606","volume":"13","author":"H Yan","year":"2022","unstructured":"Yan H, Huang C, Shen X, Li J, Zhou S, Li W. GLP-1 RAs and SGLT-2 Inhibitors for insulin resistance in nonalcoholic fatty liver disease: systematic review and network meta-analysis. Front Endocrinol (Lausanne). 2022;13:923606. https:\/\/doi.org\/10.3389\/fendo.2022.923606.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"1471_CR25","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/17512433.2024.2363838","volume":"17","author":"Y Chae","year":"2024","unstructured":"Chae Y, Kwon S-H, Nam JH, Kang E, Im J, Kim H-J, et al. Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Expert Rev Clin Pharmacol. 2024;17(8):721\u20139. https:\/\/doi.org\/10.1080\/17512433.2024.2363838.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"1471_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/03007995.2024.2442027","volume":"41","author":"FB Rivera","year":"2025","unstructured":"Rivera FB, Chin MNC, Pine PLS, Ruyeras MMJ, Galang DJC, Gandionco KM, et al. Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials. Curr Med Res Opin. 2025;41(1):185\u201397. https:\/\/doi.org\/10.1080\/03007995.2024.2442027.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"1471_CR27","doi-asserted-by":"publisher","first-page":"8936865","DOI":"10.1155\/2021\/8936865","volume":"2021","author":"S Rezaei","year":"2021","unstructured":"Rezaei S, Tabrizi R, Nowrouzi-Sohrabi P, Jalali M, Atkin SL, Al-Rasadi K, et al. GLP-1 receptor agonist effects on lipid and liver profiles in patients with nonalcoholic fatty liver disease: systematic review and meta-analysis. Can J Gastroenterol Hepatol. 2021;2021(1):8936865. https:\/\/doi.org\/10.1155\/2021\/8936865.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1471_CR28","doi-asserted-by":"publisher","first-page":"103633","DOI":"10.1016\/j.amsu.2022.103633","volume":"77","author":"S Dar","year":"2022","unstructured":"Dar S, Siddiqi AK, Alabduladhem TO, Rashid AM, Sarfraz S, Maniya T, et al. Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis. Ann Med Surg (Lond). 2022;77:103633. https:\/\/doi.org\/10.1016\/j.amsu.2022.103633.","journal-title":"Ann Med Surg (Lond)"},{"issue":"11","key":"1471_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049152","volume":"7","author":"ET Parlevliet","year":"2012","unstructured":"Parlevliet ET, Wang Y, Geerling JJ, Schr\u00f6der-Van der Elst JP, Picha K, O\u2019Neil K, et al. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS ONE. 2012;7(11). https:\/\/doi.org\/10.1371\/journal.pone.0049152.","journal-title":"PLoS ONE"},{"issue":"7","key":"1471_CR30","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2337\/dc08-2124","volume":"32","author":"B Zinman","year":"2009","unstructured":"Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32(7):1224\u201330. https:\/\/doi.org\/10.2337\/dc08-2124.","journal-title":"Diabetes Care"},{"issue":"7","key":"1471_CR31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skj\u00f8th TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687\u201399. https:\/\/doi.org\/10.1001\/jama.2015.9676.","journal-title":"JAMA"},{"issue":"4","key":"1471_CR32","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2337\/dc20-1843","volume":"44","author":"B Verg\u00e8s","year":"2021","unstructured":"Verg\u00e8s B, Duvillard L, Pais de Barros JP, Bouillet B, Baillot-Rudoni S, Rouland A, et al. Liraglutide increases the catabolism of apolipoprotein B100-containing lipoproteins in patients with type 2 diabetes and reduces proprotein convertase subtilisin\/kexin type 9 expression. Diabetes Care. 2021;44(4):1027\u201337. https:\/\/doi.org\/10.2337\/dc20-1843.","journal-title":"Diabetes Care"},{"issue":"4","key":"1471_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/osp4.133","volume":"3","author":"L Engelbrechtsen","year":"2017","unstructured":"Engelbrechtsen L, Lundgren J, Wewer Albrechtsen NJ, Mahendran Y, Iepsen EW, Finocchietto P, et al. Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. Obes Sci Pract. 2017;3(4):425\u201333. https:\/\/doi.org\/10.1002\/osp4.133.","journal-title":"Obes Sci Pract"},{"key":"1471_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164674","author":"R Le","year":"2024","unstructured":"Le R, Nguyen MT, Allahwala MA, Psaltis JP, Marathe CS, Marathe JA, et al. Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13164674.","journal-title":"J Clin Med"},{"issue":"1","key":"1471_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-018-0800-2","volume":"17","author":"AC Sposito","year":"2018","unstructured":"Sposito AC, Berwanger O, de Carvalho LSF, Saraiva JFK. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 2018;17(1):157. https:\/\/doi.org\/10.1186\/s12933-018-0800-2.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"1471_CR36","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","volume":"30","author":"DH Ryan","year":"2024","unstructured":"Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30(7):2049\u201357. https:\/\/doi.org\/10.1038\/s41591-024-02996-7.","journal-title":"Nat Med"},{"issue":"10","key":"1471_CR37","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083\u201391. https:\/\/doi.org\/10.1038\/s41591-022-02026-4.","journal-title":"Nat Med"},{"issue":"1","key":"1471_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892.","journal-title":"N Engl J Med"},{"issue":"11","key":"1471_CR39","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.1111\/bcp.14855","volume":"87","author":"LE Simental-Mend\u00eda","year":"2021","unstructured":"Simental-Mend\u00eda LE, S\u00e1nchez-Garc\u00eda A, Linden-Torres E, Simental-Mend\u00eda M. Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: A meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2021;87(11):4140\u20139. https:\/\/doi.org\/10.1111\/bcp.14855.","journal-title":"Br J Clin Pharmacol"},{"key":"1471_CR40","doi-asserted-by":"publisher","first-page":"108899","DOI":"10.1016\/j.diabres.2021.108899","volume":"177","author":"LE Simental-Mend\u00eda","year":"2021","unstructured":"Simental-Mend\u00eda LE, S\u00e1nchez-Garc\u00eda A, Linden-Torres E, Simental-Mend\u00eda M. Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials. Diab Res Clin Pract. 2021;177:108899. https:\/\/doi.org\/10.1016\/j.diabres.2021.108899.","journal-title":"Diab Res Clin Pract"},{"issue":"11","key":"1471_CR41","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1111\/bph.13481","volume":"173","author":"R El Bekay","year":"2016","unstructured":"El Bekay R, Co\u00edn-Arag\u00fcez L, Fern\u00e1ndez-Garc\u00eda D, Oliva-Olivera W, Bernal-L\u00f3pez R, Clemente-Postigo M, et al. Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes. Br J Pharmacol. 2016;173(11):1820\u201334. https:\/\/doi.org\/10.1111\/bph.13481.","journal-title":"Br J Pharmacol"},{"key":"1471_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158214","author":"Z Szekeres","year":"2024","unstructured":"Szekeres Z, Nagy A, Jahner K, Szabados E. Impact of selected glucagon-like peptide-1 receptor agonists on serum lipids, adipose tissue, and muscle metabolism-a narrative review. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25158214.","journal-title":"Int J Mol Sci"},{"key":"1471_CR43","doi-asserted-by":"publisher","first-page":"1734549","DOI":"10.3389\/fendo.2025.1734549","volume":"16","author":"T Alrasheed","year":"2025","unstructured":"Alrasheed T, Mostafa MEA, Madkhali MA, Khairy HA. Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025;16:1734549. https:\/\/doi.org\/10.3389\/fendo.2025.1734549.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1471_CR44","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.atherosclerosis.2011.12.039","volume":"221","author":"A Shiraki","year":"2012","unstructured":"Shiraki A, Oyama J, Komoda H, Asaka M, Komatsu A, Sakuma M, et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-\u03b1-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis. 2012;221(2):375\u201382. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.12.039.","journal-title":"Atherosclerosis"},{"issue":"12","key":"1471_CR45","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1139\/cjpp-2025-0148","volume":"103","author":"I Ros-Madrid","year":"2025","unstructured":"Ros-Madrid I, Cano-M\u00e1rmol RP, Ferrer-Gomez M, Ramos-Molina B. Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective. Can J Physiol Pharmacol. 2025;103(12):369\u201377. https:\/\/doi.org\/10.1139\/cjpp-2025-0148.","journal-title":"Can J Physiol Pharmacol"},{"issue":"19","key":"1471_CR46","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.122.026728","volume":"11","author":"S Xie","year":"2022","unstructured":"Xie S, Zhang M, Shi W, Xing Y, Huang Y, Fang WX, et al. Long-term activation of glucagon-like peptide-1 receptor by dulaglutide prevents diabetic heart failure and metabolic remodeling in type 2 diabetes. J Am Heart Assoc. 2022;11(19). https:\/\/doi.org\/10.1161\/jaha.122.026728.","journal-title":"J Am Heart Assoc"},{"key":"1471_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1614726","author":"X Wang","year":"2025","unstructured":"Wang X, Qi M, Yang L, Yang L, Wang X, Zhang F, et al. GLP-1 receptor agonists synergistic effects of metabolic reprogramming and cardioprotection. Front Endocrinol (Lausanne). 2025. https:\/\/doi.org\/10.3389\/fendo.2025.1614726.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1471_CR48","doi-asserted-by":"publisher","first-page":"100679","DOI":"10.1016\/j.ajpc.2024.100679","volume":"18","author":"FB Rivera","year":"2024","unstructured":"Rivera FB, Cruz LLA, Magalong JV, Ruyeras J, Aparece JP, Bantayan NRB, et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol. 2024;18:100679. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100679.","journal-title":"Am J Prev Cardiol"},{"issue":"1","key":"1471_CR49","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20(1):189. https:\/\/doi.org\/10.1186\/s12933-021-01366-8.","journal-title":"Cardiovasc Diabetol"},{"issue":"24","key":"1471_CR50","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"8","key":"1471_CR51","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/s2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605\u201317. https:\/\/doi.org\/10.1016\/s2213-8587(18)30104-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1471_CR52","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12933-023-01991-5","volume":"22","author":"ZY Peng","year":"2023","unstructured":"Peng ZY, Yang CT, Lin WH, Yao WY, Ou HT, Kuo S. Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study. Cardiovasc Diabetol. 2023;22(1):272. https:\/\/doi.org\/10.1186\/s12933-023-01991-5.","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"1471_CR53","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","volume":"38","author":"P Rossing","year":"2023","unstructured":"Rossing P, Baeres FMM, Bakris G, Bosch-Traberg H, Gislum M, Gough SCL, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023;38(9):2041\u201351. https:\/\/doi.org\/10.1093\/ndt\/gfad009.","journal-title":"Nephrol Dial Transplant"},{"key":"1471_CR54","unstructured":"Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis. https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=166327 Accessed 1 February 2026."},{"key":"1471_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cells13010065","author":"SS Wilbon","year":"2023","unstructured":"Wilbon SS, Kolonin MG. GLP1 receptor agonists-effects beyond obesity and diabetes. Cells. 2023. https:\/\/doi.org\/10.3390\/cells13010065.","journal-title":"Cells"},{"issue":"1","key":"1471_CR56","doi-asserted-by":"publisher","first-page":"e12268","DOI":"10.1002\/trc2.12268","volume":"8","author":"CH N\u00f8rgaard","year":"2022","unstructured":"N\u00f8rgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, M\u00f8ller DV, et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers Dement (N Y). 2022;8(1):e12268. https:\/\/doi.org\/10.1002\/trc2.12268.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"7","key":"1471_CR57","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","volume":"19","author":"T Cukierman-Yaffe","year":"2020","unstructured":"Cukierman-Yaffe T, Gerstein HC, Colhoun HM, Diaz R, Garc\u00eda-P\u00e9rez L-E, Lakshmanan M, et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. The Lancet Neurology. 2020;19(7):582\u201390. https:\/\/doi.org\/10.1016\/S1474-4422(20)30173-3.","journal-title":"The Lancet Neurology"},{"issue":"6","key":"1471_CR58","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41366-020-0535-5","volume":"44","author":"F Vadini","year":"2020","unstructured":"Vadini F, Simeone PG, Boccatonda A, Guagnano MT, Liani R, Tripaldi R, et al. Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. Int J Obes. 2020;44(6):1254\u201363. https:\/\/doi.org\/10.1038\/s41366-020-0535-5.","journal-title":"Int J Obes"},{"key":"1471_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","volume":"349","author":"S Coassin","year":"2022","unstructured":"Coassin S, Kronenberg F. Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene. Atherosclerosis. 2022;349:17\u201335. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.003.","journal-title":"Atherosclerosis"},{"issue":"12","key":"1471_CR60","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk insights from the FOURIER trial. Circulation. 2019;139(12):1483\u201392. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037184.","journal-title":"Circulation"},{"issue":"2","key":"1471_CR61","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/med.0000000000000237","volume":"23","author":"S Tsimikas","year":"2016","unstructured":"Tsimikas S. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk. Curr Opin Endocrinol Diabetes Obes. 2016;23(2):157\u201364. https:\/\/doi.org\/10.1097\/med.0000000000000237.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"10","key":"1471_CR62","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/phar.2851","volume":"43","author":"IS Alhomoud","year":"2023","unstructured":"Alhomoud IS, Talasaz A, Mehta A, Kelly MS, Sisson EM, Bucheit JD, et al. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: a review of current and emerging therapies. Pharmacotherapy. 2023;43(10):1051\u201363. https:\/\/doi.org\/10.1002\/phar.2851.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"1471_CR63","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41569-023-00937-4","volume":"21","author":"S Tsimikas","year":"2024","unstructured":"Tsimikas S, Witztum JL. Oxidized phospholipids in cardiovascular disease. Nat Rev Cardiol. 2024;21(3):170\u201391. https:\/\/doi.org\/10.1038\/s41569-023-00937-4.","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"1471_CR64","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","volume":"16","author":"MB Boffa","year":"2019","unstructured":"Boffa MB, Koschinsky ML. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat Rev Cardiol. 2019;16(5):305\u201318. https:\/\/doi.org\/10.1038\/s41569-018-0153-2.","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"1471_CR65","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/eurjpc\/zwae032","volume":"31","author":"PR Kamstrup","year":"2024","unstructured":"Kamstrup PR, Neely RDG, Nissen S, Landmesser U, Haghikia A, Costa-Scharplatz M, et al. Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research. Eur J Prev Cardiol. 2024;31(7):903\u201314. https:\/\/doi.org\/10.1093\/eurjpc\/zwae032.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"1471_CR66","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/mol.0000000000000855","volume":"33","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG. Consensus and guidelines on lipoprotein(a) - seeing the forest through the trees. Curr Opin Lipidol. 2022;33(6):342\u201352. https:\/\/doi.org\/10.1097\/mol.0000000000000855.","journal-title":"Curr Opin Lipidol"},{"issue":"11","key":"1471_CR67","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2511393","volume":"25","author":"M Manzato","year":"2024","unstructured":"Manzato M, Wright RS, Jaffe AS, Vasile VC. Lipoprotein (a): underrecognized risk with a promising future. Rev Cardiovasc Med. 2024;25(11). https:\/\/doi.org\/10.31083\/j.rcm2511393.","journal-title":"Rev Cardiovasc Med"},{"issue":"24","key":"1471_CR68","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","volume":"41","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehz310.","journal-title":"Eur Heart J"},{"issue":"1","key":"1471_CR69","doi-asserted-by":"publisher","first-page":"17887","DOI":"10.1038\/s41598-018-36204-7","volume":"8","author":"A Sahebkar","year":"2018","unstructured":"Sahebkar A, Simental-Mend\u00eda LE, Pirro M, Banach M, Watts GF, Sirtori C, et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018;8(1):17887. https:\/\/doi.org\/10.1038\/s41598-018-36204-7.","journal-title":"Sci Rep"},{"issue":"4","key":"1471_CR70","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40265-018-0870-1","volume":"78","author":"K Awad","year":"2018","unstructured":"Awad K, Mikhailidis DP, Katsiki N, Muntner P, Banach M. Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials. Drugs. 2018;78(4):453\u201362. https:\/\/doi.org\/10.1007\/s40265-018-0870-1.","journal-title":"Drugs"},{"key":"1471_CR71","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000963","author":"I Farmakis","year":"2021","unstructured":"Farmakis I, Doundoulakis I, Pagiantza A, Zafeiropoulos S, Antza C, Karvounis H, et al. Lipoprotein(a) reduction with proprotein convertase subtilisin\/kexin type 9 inhibitors: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2021. https:\/\/doi.org\/10.1097\/FJC.0000000000000963.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"24","key":"1471_CR72","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1093\/eurheartj\/ehaa171","volume":"41","author":"LCA Stiekema","year":"2020","unstructured":"Stiekema LCA, Prange KHM, Hoogeveen RM, Verweij SL, Kroon J, Schnitzler JG, et al. Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). Eur Heart J. 2020;41(24):2262\u201371. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa171.","journal-title":"Eur Heart J"},{"issue":"17","key":"1471_CR73","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","volume":"62","author":"JJ Albers","year":"2013","unstructured":"Albers JJ, Slee A, O\u2019Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes. J Am Coll Cardiol. 2013;62(17):1575\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2013.06.051.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1471_CR74","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jacl.2023.02.002","volume":"17","author":"PM Ridker","year":"2023","unstructured":"Ridker PM, Lei L, Ray KK, Ballantyne CM, Bradwin G, Rifai N. Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial. J Clin Lipidol. 2023;17(2):297\u2013302. https:\/\/doi.org\/10.1016\/j.jacl.2023.02.002.","journal-title":"J Clin Lipidol"},{"key":"1471_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2021.100060","volume":"62","author":"RS Rosenson","year":"2021","unstructured":"Rosenson RS. Existing and emerging therapies for the treatment of familial hypercholesterolemia. J Lipid Res. 2021;62. https:\/\/doi.org\/10.1016\/j.jlr.2021.100060.","journal-title":"J Lipid Res"},{"key":"1471_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2025.06.004","author":"HS Bhatia","year":"2025","unstructured":"Bhatia HS, Bajaj A, Goonewardena SN, Moriarty PM. Pelacarsen: mechanism of action and Lp(a)-lowering effect. J Clin Lipidol. 2025. https:\/\/doi.org\/10.1016\/j.jacl.2025.06.004.","journal-title":"J Clin Lipidol"},{"issue":"10","key":"1471_CR77","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1194\/jlr.R056549","volume":"57","author":"E Waldmann","year":"2016","unstructured":"Waldmann E, Parhofer KG. Lipoprotein apheresis to treat elevated lipoprotein (a). J Lipid Res. 2016;57(10):1751\u20137. https:\/\/doi.org\/10.1194\/jlr.R056549.","journal-title":"J Lipid Res"},{"issue":"3","key":"1471_CR78","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"MJ Landray","year":"2014","unstructured":"Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203\u201312. https:\/\/doi.org\/10.1056\/NEJMoa1300955.","journal-title":"N Engl J Med"},{"issue":"12","key":"1471_CR79","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jacc.2021.01.051","volume":"77","author":"S Tsimikas","year":"2021","unstructured":"Tsimikas S, Moriarty PM, Stroes ES. Emerging RNA therapeutics to lower blood levels of Lp(a): JACC focus seminar 2\/4. J Am Coll Cardiol. 2021;77(12):1576\u201389. https:\/\/doi.org\/10.1016\/j.jacc.2021.01.051.","journal-title":"J Am Coll Cardiol"},{"key":"1471_CR80","doi-asserted-by":"publisher","unstructured":"O'Donoghue ML, G. L\u00f3pez JA, Knusel B, Gencer B, Wang H, Wu Y, et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am Heart J. 2022;251:61\u20139. https:\/\/doi.org\/10.1016\/j.ahj.2022.05.004.","DOI":"10.1016\/j.ahj.2022.05.004"},{"issue":"7","key":"1471_CR81","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14304\/surya.jpr.v4n7.5","volume":"4","author":"J Chery","year":"2016","unstructured":"Chery J. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J. 2016;4(7):35\u201350. https:\/\/doi.org\/10.14304\/surya.jpr.v4n7.5.","journal-title":"Postdoc J"},{"issue":"20","key":"1471_CR82","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O'Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Rosenson RS, Gencer B, L\u00f3pez JAG, Lepor NE, Baum SJ, et al. Small Interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387(20):1855\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2211023.","journal-title":"N Engl J Med"},{"issue":"17","key":"1471_CR83","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","volume":"392","author":"E Nissen Steven","year":"2025","unstructured":"Nissen Steven E, Ni W, Shen X, Wang Q, Navar Ann M, Nicholls Stephen J, et al. Lepodisiran \u2014 a long-duration small interfering RNA targeting lipoprotein(a). N Engl J Med. 2025;392(17):1673\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2415818.","journal-title":"N Engl J Med"},{"issue":"9","key":"1471_CR84","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jacc.2024.05.058","volume":"84","author":"ML O'Donoghue","year":"2024","unstructured":"O\u2019Donoghue ML, Rosenson RS, L\u00f3pez JAG, Lepor NE, Baum SJ, Stout E, et al. The Off-treatment effects of olpasiran on lipoprotein(a) Lowering: OCEAN(a)-DOSE extension period results. J Am Coll Cardiol. 2024;84(9):790\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2024.05.058.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"1471_CR85","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.2024.21957","volume":"332","author":"SE Nissen","year":"2024","unstructured":"Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, et al. Zerlasiran\u2014a small-interfering RNA targeting lipoprotein(a): A Phase 2 randomized clinical trial. JAMA. 2024;332(23):1992\u20132002. https:\/\/doi.org\/10.1001\/jama.2024.21957.","journal-title":"JAMA"},{"issue":"3","key":"1471_CR86","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.2024.24017","volume":"333","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Ni W, Rhodes GM, Nissen SE, Navar AM, Michael LF, et al. Oral muvalaplin for lowering of lipoprotein(a): A randomized clinical trial. JAMA. 2025;333(3):222\u201331. https:\/\/doi.org\/10.1001\/jama.2024.24017.","journal-title":"JAMA"},{"key":"1471_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063537","author":"G Tsioulos","year":"2024","unstructured":"Tsioulos G, Kounatidis D, Vallianou NG, Poulaki A, Kotsi E, Christodoulatos GS, et al. Lipoprotein(a) and atherosclerotic cardiovascular disease: where do we stand? Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25063537.","journal-title":"Int J Mol Sci"},{"issue":"10057","key":"1471_CR88","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"NJ Viney","year":"2016","unstructured":"Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. The Lancet. 2016;388(10057):2239\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(16)31009-1.","journal-title":"The Lancet"},{"issue":"1","key":"1471_CR89","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jacl.2022.12.001","volume":"17","author":"E Karwatowska-Prokopczuk","year":"2023","unstructured":"Karwatowska-Prokopczuk E, Lesogor A, Yan J-H, Hurh E, Hoenlinger A, Margolskee A, et al. Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects. J Clin Lipidol. 2023;17(1):181\u20138. https:\/\/doi.org\/10.1016\/j.jacl.2022.12.001.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"1471_CR90","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif J-C, Baum Seth J, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1905239.","journal-title":"N Engl J Med"},{"key":"1471_CR91","unstructured":"ClinicalTrials.gov: A study to investigate the effect of lepodisiran on the reduction of major adverse cardiovascular events in adults with elevated lipoprotein(a) - ACCLAIM-Lp(a). https:\/\/clinicaltrials.gov\/study\/NCT06292013 Accessed January 1, 2026."},{"issue":"21","key":"1471_CR92","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","volume":"330","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, et al. Lepodisiran, an extended-duration short interfering rna targeting lipoprotein(a): a randomized dose-ascending clinical trial. JAMA. 2023;330(21):2075\u201383. https:\/\/doi.org\/10.1001\/jama.2023.21835.","journal-title":"JAMA"},{"issue":"17","key":"1471_CR93","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2022.5050","volume":"327","author":"SE Nissen","year":"2022","unstructured":"Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA. 2022;327(17):1679\u201387. https:\/\/doi.org\/10.1001\/jama.2022.5050.","journal-title":"JAMA"},{"key":"1471_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60060908","author":"M Hachu\u0142a","year":"2024","unstructured":"Hachu\u0142a M, Kosowski M, Basiak M, Okopie\u0144 B. Influence of dulaglutide on serum biomarkers of atherosclerotic plaque instability: an interventional analysis of cytokine profiles in diabetic subjects-a pilot study. Medicina (Kaunas). 2024. https:\/\/doi.org\/10.3390\/medicina60060908.","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"1471_CR95","doi-asserted-by":"publisher","first-page":"108436","DOI":"10.1016\/j.jdiacomp.2023.108436","volume":"37","author":"A Bechlioulis","year":"2023","unstructured":"Bechlioulis A, Markozannes G, Chionidi I, Liberopoulos E, Naka KK, Ntzani EE, et al. The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study. J Diabetes Complications. 2023;37(4):108436. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108436.","journal-title":"J Diabetes Complications"},{"key":"1471_CR96","unstructured":"The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a). https:\/\/trial.medpath.com\/clinical-trial\/9d75bbe2da7f93f2\/nct02501850-effect-glp-1-receptor-agonists-blood-lipoprotein Accessed 1 February 2026."},{"issue":"3","key":"1471_CR97","doi-asserted-by":"publisher","first-page":"e896","DOI":"10.1210\/clinem\/dgz111","volume":"105","author":"RPF Dullaart","year":"2020","unstructured":"Dullaart RPF. Lipoprotein(a): the renaissance of an enigmatic lipoprotein. J Clin Endocrinol Metab. 2020;105(3):e896\u20138. https:\/\/doi.org\/10.1210\/clinem\/dgz111.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01471-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01471-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01471-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:47:14Z","timestamp":1792086434000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01471-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1471"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01471-7","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article is based on previously published studies and does not contain any new studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"101"}}